Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer



Status:Completed
Conditions:Ovarian Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:6/3/2018
Start Date:December 12, 2011
End Date:January 27, 2018

Use our guide to learn which trials are right for you!

A Randomized Phase IIB Evaluation of Weekly Paclitaxel (NSC #673089) Plus Pazopanib (NSC #737754) Versus Weekly Paclitaxel Plus Placebo in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma

This randomized phase II trial studies how well paclitaxel when given together with or
without pazopanib hydrochloride works in treating patients with ovarian epithelial, fallopian
tube, or peritoneal cavity cancer that is persistent or has come back. Drugs used in
chemotherapy, such as paclitaxel work in different ways to stop the growth of tumor cells,
either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Pazopanib hydrochloride may stop the growth of tumor cells by blocking blood flow
to the tumor or by blocking some of the enzymes needed for cell growth. It is not yet known
whether paclitaxel is more effective when given with or without pazopanib hydrochloride in
treating ovarian epithelial, fallopian tube, and peritoneal cavity cancer.

PRIMARY OBJECTIVES:

I. To estimate the progression-free survival hazard ratio of the combination of weekly
paclitaxel and pazopanib (pazopanib hydrochloride) compared to weekly paclitaxel and placebo
in patients with persistent or recurrent ovarian, fallopian tube, or primary peritoneal
cancer.

SECONDARY OBJECTIVES:

I. To determine the frequency and severity of adverse events as assessed by Common
Terminology Criteria for Adverse Events (CTCAE).

II. To estimate and compare the proportion of patients responding to therapy by Response
Evaluation Criteria in Solid Tumors (RECIST), cancer antigen 125 (CA125) response, the
overall survival (OS), and the duration of response in each arm.

TERTIARY OBJECTIVES:

I. To explore the association between plasma cytokines and angiogenic markers and
progression-free and overall survival.

II. To explore the association between single-nucleotide polymorphisms (SNPs) and
progression-free and overall survival.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive paclitaxel intravenously (IV) over 1 hour on days 1, 8, and 15 and
placebo orally (PO) daily on days 1-28.

ARM II: Patients receive paclitaxel as in Arm I and pazopanib hydrochloride PO daily on days
1-28.

In both arms, courses repeat every 28 days in the absence of disease progression or
unacceptable toxicity.

After completion of study therapy, patients are followed up every 3 months for 2 years and
then every 6 months for 3 years.

Inclusion Criteria:

- Patients must have recurrent or persistent epithelial ovarian, fallopian tube, or
primary peritoneal carcinoma; histologic documentation of the original primary tumor
is required via the pathology report

- Patients must have measurable disease or non-measurable (detectable) disease

- Measurable disease is defined as at least one lesion that can be accurately
measured in at least one dimension (longest diameter to be recorded); each lesion
must be greater than or equal to 10 mm when measured by computed tomography (CT),
magnetic resonance imaging (MRI), or caliper measurement by clinical exam; or
greater than or equal to 20 mm when measured by chest x-ray; lymph nodes must be
greater than or equal to 15 mm in short axis when measured by CT or MRI

- Non-measurable (detectable) disease in a patient is defined in this protocol as
one who does not have measurable disease but has at least one of the following
conditions:

- Ascites and/or pleural effusion attributed to tumor

- Solid and/or cystic abnormalities on radiographic imaging that do not meet
RECIST 1.1 definitions for target lesions

- Patients with measurable disease must have at least one "target lesion" to be used to
assess response on this protocol as defined by RECIST 1.1; tumors within a previously
irradiated field will be designated as "non-target" lesions unless progression is
documented or a biopsy is obtained to confirm persistence at least 90 days following
completion of radiation therapy

- Patients must not be eligible for a higher priority Gynecology Oncology Group (GOG)
protocol, if one exists; in general, this would refer to any active GOG phase III or
Rare Tumor protocol for the same patient population; in addition, patients must not be
eligible for the currently active phase II cytotoxic protocol in platinum resistant
disease

- Patients who have received one prior regimen must have a GOG performance status of 0,
1, or 2

- Patients who have received two or three prior regimens must have a GOG performance
status of 0 or 1

- Recovery from effects of recent surgery, radiotherapy, or chemotherapy

- Patients should be free of active infection requiring antibiotics (with the exception
of uncomplicated urinary tract infection [UTI])

- Any hormonal therapy directed at the malignant tumor must be discontinued at least one
week prior to registration

- Any other prior therapy directed at the malignant tumor, including chemotherapy,
biological/targeted (non-cytotoxic) agents, and immunologic agents, must be
discontinued at least three weeks prior to registration; chimeric or human or
humanized monoclonal antibodies (including bevacizumab) or vascular endothelial growth
factor (VEGF) receptor fusion proteins (including VEGF TRAP/aflibercept) must be
discontinued for at least 12 weeks prior to registration

- At least 4 weeks must have elapsed since the patient underwent any major surgery
(e.g., major: laparotomy, laparoscopy, thoracotomy, video-assisted thorascopic surgery
[VATS]); there is no restriction on minor procedures (e.g., minor: central venous
access catheter placement, ureteral stent placement or exchange, paracentesis,
thoracentesis)

- Patients must have had one prior platinum-based chemotherapeutic regimen for
management of primary disease containing carboplatin, cisplatin, or another
organoplatinum compound; this initial treatment may have included intraperitoneal
therapy, consolidation, biologic/targeted (non-cytotoxic) agents (e.g., bevacizumab),
or extended therapy administered after surgical or non-surgical assessment; if
patients were treated with paclitaxel for their primary disease, this can have been
given weekly or every 3 weeks

- Patients are allowed to receive, but are not required to receive, two additional
cytotoxic regimens for management of recurrent or persistent disease, with no more
than 1 non-platinum, non-taxane regimen; treatment with weekly paclitaxel for
recurrent or persistent disease is NOT allowed

- Patients are allowed to receive, but are not required to receive, biologic/targeted
(non-cytotoxic) therapy as part of their primary treatment regimen

- Patients must have NOT received any biologic/targeted (non-cytotoxic) therapy
targeting the VEGF and/or platelet-derived growth factor (PDGF) pathways for
management of recurrent or persistent disease

- For the purposes of this study, poly (ADP-ribose) polymerase (PARP) inhibitors will be
considered "cytotoxic"; patients are allowed to receive, but are not required to
receive, PARP inhibitors for management of primary or recurrent/persistent disease
(either alone or in combination with cytotoxic chemotherapy); PARP inhibitors will NOT
count as a prior regimen when given alone

- Absolute neutrophil count (ANC) greater than or equal to 1,500/mcL

- Platelets greater than or equal to 100,000/mcL

- Hemoglobin greater than or equal to 9 g/dL

- Prothrombin time (PT) such that international normalized ratio (INR) is less than or
equal to 1.5 x upper limit of normal (ULN) (or an in-range INR, usually between 2 and
3, if a patient is on a stable dose of therapeutic warfarin)

- Partial thromboplastin time (PTT) less than or equal to 1.5 x ULN

- Creatinine less than or equal to 1.5 x institutional ULN

- Urine protein should be screened by urinalysis; if urine protein is 2+ or higher,
24-hour urine protein should be obtained and the level must be < 1000 mg (< 1.0 g/24
hours [hrs]) for patient enrollment

- Bilirubin less than or equal to 1.5 x ULN

- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal
to 2.5 x ULN

- Subjects who have BOTH bilirubin greater than ULN and AST/ALT greater than ULN are not
eligible

- Alkaline phosphatase less than or equal to 2.5 x ULN

- Patients must have normal baseline thyroid function tests (thyroid-stimulating hormone
[TSH], T3, T4); a history of hypothyroidism and/or hyperthyroidism is allowed, as long
as the patient has stable well-controlled thyroid function for a minimum of 2 months

- Neuropathy (sensory and motor) less than or equal to grade 1

- Patients of childbearing potential must have a negative pregnancy test prior to the
study entry and be practicing an effective form of contraception; pregnant women are
excluded from this study

- Patients must have signed an approved informed consent and authorization permitting
the release of personal health information

- Patients must be capable of taking and absorbing oral medications; a patient must be
clear of the following:

- Any lesion, whether induced by tumor, radiation, or other conditions, which makes
it difficult to swallow tablets

- Prior surgical procedures affecting absorption including, but not limited to
major resection of stomach or small bowel

- Active peptic ulcer disease

- Malabsorption syndrome

- Any concomitant medications that are associated with a risk of corrected QT (QTc)
prolongation and/or Torsades de Pointes should be discontinued or replaced with drugs
that do not carry these risks, if possible; patients who must take medication with a
risk of possible risk of Torsades de Pointes should be watched carefully for symptoms
of QTc prolongation, such as syncope

- Patients with personal or family history of congenital long QTc syndrome are NOT
eligible

- Strong inhibitors of cytochrome P-450 system (CYP)3A4 are prohibited

- Strong inducers of CYP3A4 are prohibited

- Concomitant use of agents with narrow therapeutic windows that are metabolized by
CYP3A4, CYP2D6, or CYP2C8 is not recommended

Exclusion Criteria:

- Patients who have had previous treatment with pazopanib; patients who have had
previous treatment with weekly paclitaxel for recurrent or persistent disease

- Patients with a history of other invasive malignancies, with the exception of
non-melanoma skin cancer and other specific malignancies are excluded if there is any
evidence of other malignancy being present within the last three years; patients are
also excluded if their previous cancer treatment contraindicates this protocol therapy

- Patients who have received prior radiotherapy to any portion of the abdominal cavity
or pelvis within the last three years are excluded; prior radiation for localized
cancer of the breast, head and neck, or skin is permitted, provided that it was
completed more than three years prior to registration, and the patient remains free of
recurrent or metastatic disease

- Patients who have received prior chemotherapy for any abdominal or pelvic tumor OTHER
THAN for the treatment of ovarian, fallopian tube, or primary peritoneal cancer within
the last three years; patients may have received prior adjuvant chemotherapy for
localized breast cancer, provided that it was completed more than three years prior to
registration, and the patient remains free of recurrent or metastatic disease

- Patients with clinically significant cardiovascular disease; this includes:

- Uncontrolled hypertension, defined as systolic greater than 140 mm Hg or
diastolic greater than 90 mm Hg despite antihypertensive medications

- Congenital long QT syndrome or baseline QTc greater than 480 milliseconds

- Myocardial infarction or unstable angina within 6 months prior to registration

- New York Heart Association (NYHA) class II or greater congestive heart failure

- History of serious ventricular arrhythmia (i.e., ventricular tachycardia or
ventricular fibrillation) or serious cardiac arrhythmia requiring medication

- This does not include asymptomatic atrial fibrillation with controlled
ventricular rate

- Patients who have received prior treatment with an anthracycline (including
doxorubicin and/or liposomal doxorubicin) must have an echocardiogram assessment
and are excluded if they have an ejection fraction less than 50%

- CTCAE grade 2 or greater peripheral vascular disease (at least brief [less than
24 hours] episodes of ischemia managed non-surgically and without permanent
deficit)

- History of cardiac angioplasty or stenting within 6 months prior to registration

- History of coronary artery bypass graft surgery within 6 months prior to
registration

- Arterial thrombosis within 6 months prior to registration

- Patients with serious non-healing wound, ulcer, or bone fracture; this includes
history of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess
within 28 days prior to the first date of study treatment

- Patients with active bleeding or pathologic conditions that carry high risk of
bleeding, such as known bleeding disorder, coagulopathy, or tumor involving major
vessels

- Patients with history or evidence upon physical examination of central nervous system
(CNS) disease, including primary brain tumor, seizures which are not controlled with
non-enzyme inducing anticonvulsants, any brain metastases, or history of
cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or
subarachnoid hemorrhage within six months prior to the first date of study treatment

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to pazopanib

- Known human immunodeficiency virus (HIV)-positive subjects on combination
antiretroviral therapy

- Patients with any condition that may increase the risk of gastrointestinal bleeding or
gastrointestinal perforation, including:

- Active peptic ulcer disease

- Known gastrointestinal intraluminal metastatic lesions (gastrointestinal serosa
metastatic lesions are permitted)

- Inflammatory bowel disease (e.g., ulcerative colitis, Crohn's disease)

- Patients with clinical symptoms or signs of gastrointestinal obstruction

- Patients who require parenteral hydration and/or nutrition

- Patients who are pregnant or nursing

- History of hemoptysis in excess of 2.5 mL (½ teaspoon) within 8 weeks prior to first
dose of pazopanib

- Uncontrolled intercurrent illness including, but not limited to, psychiatric
illness/social situations that would limit compliance with study requirements
We found this trial at
142
sites
929 N St Francis St
Wichita, Kansas 67214
(316) 268-5775
Via Christi Regional Medical Center Via Christi Health's rich history of serving the people of...
?
mi
from
Wichita, KS
Click here to add this to my saved trials
Bremerton, Washington 98310
?
mi
from
Bremerton, WA
Click here to add this to my saved trials
1 Hurley Plaza
Flint, Michigan 48503
(810) 262-9000
Hurley Medical Center From its founding in 1908, Hurley Medical Center has devoted itself to...
?
mi
from
Flint, MI
Click here to add this to my saved trials
2500 N State St
Jackson, Mississippi 39216
(601) 984-1000
University of Mississippi Medical Center The University of Mississippi Medical Center, located in Jackson, is...
?
mi
from
Jackson, MS
Click here to add this to my saved trials
600 8th Street South
Saint Petersburg, Florida 33701
?
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Seattle, Washington 98104
?
mi
from
Seattle, WA
Click here to add this to my saved trials
825 Eastlake Ave E
Seattle, Washington 98109
(206) 288-7222
Seattle Cancer Care Alliance Seattle Cancer Care Alliance (SCCA) is a cancer treatment center that...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
1100 Fairview Avenue North
Seattle, Washington 98109
(206) 667-5000
Fred Hutchinson Cancer Research Center At Fred Hutchinson Cancer Research Center, our interdisciplinary teams of...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
601 South Sherman Street
Spokane, Washington 99202
(509) 228-1000
Cancer Care Northwest - Spokane South Cancer Care Northwest is the Inland Northwest’s premier cancer...
?
mi
from
Spokane, WA
Click here to add this to my saved trials
1200 Old York Road
Abington, Pennsylvania 19001
(215) 481–2000
Abington Memorial Hospital Abington Memorial Hospital (AMH) is a 665-bed, regional referral center and teaching...
?
mi
from
Abington, PA
Click here to add this to my saved trials
?
mi
from
Akron, OH
Click here to add this to my saved trials
Albany, New York 12208
?
mi
from
Albany, NY
Click here to add this to my saved trials
Ames, Iowa 50010
?
mi
from
Ames, IA
Click here to add this to my saved trials
5301 McAuley Drive
Ann Arbor, Michigan 48197
734-712-3456
Saint Joseph Mercy Hospital St. Joseph Mercy Ann Arbor Hospital is a 537-bed teaching hospital...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Ann Arbor, Michigan 48106
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
6701 N Charles St
Baltimore, Maryland 21204
(443) 849-2000
Greater Baltimore Medical Center The 255-bed medical center (acute and sub-acute care) is located on...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
2401 W Belvedere Ave
Baltimore, Maryland 21215
(410) 601-9000
Sinai Hospital of Baltimore Sinai Hospital of Baltimore provides a broad array of high-quality, cost-effective...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
401 North Broadway
Baltimore, Maryland 21287
410-955-5000
Johns Hopkins University-Sidney Kimmel Cancer Center The name Johns Hopkins has become synonymous with excellence...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
265 Fremont St
Battle Creek, Michigan 49017
(269) 245-8166
Bronson Battle Creek As a proud member of the Battle Creek community, we believe everyone...
?
mi
from
Battle Creek, MI
Click here to add this to my saved trials
Bellingham, Washington 98226
?
mi
from
Bellingham, WA
Click here to add this to my saved trials
Big Rapids, Michigan 49307
?
mi
from
Big Rapids, MI
Click here to add this to my saved trials
?
mi
from
Boise, ID
Click here to add this to my saved trials
?
mi
from
Bremerton, WA
Click here to add this to my saved trials
?
mi
from
Burbank, CA
Click here to add this to my saved trials
Burlington, Massachusetts 01805
?
mi
from
Burlington, MA
Click here to add this to my saved trials
?
mi
from
Camden, NJ
Click here to add this to my saved trials
505 S Plummer Ave
Chanute, Kansas 66720
(620) 431-7580
Cancer Center of Kansas, PA - Chanute Dr. H.E. Hynes founded Cancer Center of Kansas,...
?
mi
from
Chanute, KS
Click here to add this to my saved trials
Chapel Hill, North Carolina 27599
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Charlotte, North Carolina 28204
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
303 East Superior Street
Chicago, Illinois 60611
?
mi
from
Chicago, IL
Click here to add this to my saved trials
1653 W. Congress Parkway
Chicago, Illinois 60612
(312) 942-5000
Rush University Medical Center Rush University Medical Center encompasses a 664-bed hospital serving adults and...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
10900 Euclid Ave
Cleveland, Ohio 44106
216-368-2000
Case Western Reserve Univ Continually ranked among America's best colleges, Case Western Reserve University has...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
18101 Lorain Avenue
Cleveland, Ohio 44111
216.476.7000
Cleveland Clinic Cancer Center at Fairview Hospital Fairview Hospital is a 488-bed hospital located at...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
2049 E 100th St
Cleveland, Ohio 44106
(216) 444-2200
Cleveland Clinic Foundation The Cleveland Clinic (formally known as The Cleveland Clinic Foundation) is a...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
3535 Olentangy River Rd
Columbus, Ohio 43214
(614) 566-5000
Riverside Methodist Hospital Serving central Ohio since 1892, Riverside Methodist Hospital is consistently ranked one...
?
mi
from
Columbus, OH
Click here to add this to my saved trials
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Dearborn, Michigan 48124
?
mi
from
Dearborn, MI
Click here to add this to my saved trials
1111 6th Ave
Des Moines, Iowa 50314
(515) 247-3121
Mercy Medical Center - Des Moines Mercy Medical Center
?
mi
from
Des Moines, IA
Click here to add this to my saved trials
700 E University Ave
Des Moines, Iowa 50316
(515) 263-5612
Iowa Lutheran Hospital Iowa Lutheran Hospital has a long history of serving the Des Moines...
?
mi
from
Des Moines, IA
Click here to add this to my saved trials
1200 Pleasant St
Des Moines, Iowa 50309
(515) 241-6212
Iowa Methodist Medical Center Iowa Methodist Medical Center was established in 1901 in a single...
?
mi
from
Des Moines, IA
Click here to add this to my saved trials
?
mi
from
Des Moines, IA
Click here to add this to my saved trials
?
mi
from
Des Moines, IA
Click here to add this to my saved trials
?
mi
from
Des Moines, IA
Click here to add this to my saved trials
22101 Moross Rd
Detroit, Michigan 48236
(313) 343-4000
Saint John Hospital and Medical Center Founded in 1952, St. John Hospital and Medical Center...
?
mi
from
Detroit, MI
Click here to add this to my saved trials
2020 Central Ave
Dodge City, Kansas 67801
(620) 227-2488
Cancer Center of Kansas, PA - Dodge City Dr. H.E. Hynes founded Cancer Center of...
?
mi
from
Dodge City, KS
Click here to add this to my saved trials
900 W. Clairemont Ave.
Eau Claire, Wisconsin 54701
715 839-3956
Marshfield Clinic Cancer Center at Sacred Heart Marshfield Clinic Cancer Care at Sacred Heart Hospital...
?
mi
from
Eau Claire, WI
Click here to add this to my saved trials
700 West Central
El Dorado, Kansas 67042
(316) 889-0099
Cancer Center of Kansas, PA - El Dorado Dr. H.E. Hynes founded Cancer Center of...
?
mi
from
El Dorado, KS
Click here to add this to my saved trials
Elkton, Maryland 21921
?
mi
from
Elkton, MD
Click here to add this to my saved trials
1717 13th St
Everett, Washington 98201
(425) 297-5500
Providence Regional Cancer Partnership Founded in 2007, the Providence Regional Cancer Partnership is the result...
?
mi
from
Everett, WA
Click here to add this to my saved trials
Farmington, Connecticut 06030
?
mi
from
Farmington, CT
Click here to add this to my saved trials
Fort Scott, Kansas 66701
(620) 223-8589
Cancer Center of Kansas - Fort Scott Dr. H.E. Hynes founded Cancer Center of Kansas,...
?
mi
from
Fort Scott, KS
Click here to add this to my saved trials
?
mi
from
Fort Worth, TX
Click here to add this to my saved trials
743 Spring Street Northeast
Gainesville, Georgia 30501
?
mi
from
Gainesville, GA
Click here to add this to my saved trials
1 Genesys Pkwy
Grand Blanc, Michigan 48439
(810) 606-5000
Genesys Regional Medical Center Genesys Health System, a member of Ascension Health, is a group...
?
mi
from
Grand Blanc, MI
Click here to add this to my saved trials
?
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Grand Rapids, Michigan 49503
?
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
100 Michigan St NE
Grand Rapids, Michigan 49503
(616) 391-1774
Spectrum Health at Butterworth Campus Butterworth Hospital is one of four facilities that make up...
?
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
835 S Van Buren St
Green Bay, Wisconsin 54301
?
mi
from
Green Bay, WI
Click here to add this to my saved trials
835 S. Van Buren St.
Green Bay, Wisconsin 54301
(920) 884-3135
Green Bay Oncology at Saint Vincent Hospital We are one of a select few physician...
?
mi
from
Green Bay, WI
Click here to add this to my saved trials
1726 Shawano Ave.
Green Bay, Wisconsin 54303
(920) 884-3135
Green Bay Oncology Limited at Saint Mary's Hospital We are one of a select few...
?
mi
from
Green Bay, WI
Click here to add this to my saved trials
Greenville, South Carolina 29605
?
mi
from
Greenville, SC
Click here to add this to my saved trials
Greenville, South Carolina 29615
?
mi
from
Greenville, SC
Click here to add this to my saved trials
?
mi
from
Hartford, CT
Click here to add this to my saved trials
80 Seymour St
Hartford, Connecticut 6102
(860) 545-5000
The Hartford Hospital Hartford Hospital is the major teaching hospital affiliated with the University of...
?
mi
from
Hartford, CT
Click here to add this to my saved trials
?
mi
from
Hinsdale, IL
Click here to add this to my saved trials
Honolulu, Hawaii 96813
?
mi
from
Honolulu, HI
Click here to add this to my saved trials
800 W. Laurel
Independence, Kansas 67301
620-331-4099
Cancer Center of Kansas-Independence Dr. H.E. Hynes founded Cancer Center of Kansas, P. A. in...
?
mi
from
Independence, KS
Click here to add this to my saved trials
Indianapolis, Indiana 46260
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
535 Barnhill Dr
Indianapolis, Indiana 46202
(888) 600-4822
Indiana University Melvin and Bren Simon Cancer Center At the IU Simon Cancer Center, more...
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
205 NE Ave
Jackson, Michigan 49201
(517) 788-4800
Allegiance Health Allegiance Health is a community-owned and locally-governed health system in Jackson, Michigan. We...
?
mi
from
Jackson, MI
Click here to add this to my saved trials
1102 W 32nd St
Joplin, Missouri 64804
(417) 347-1111
Freeman Health System Freeman in Joplin, Missouri, is a 485-bed, three-hospital system providing comprehensive healthcare...
?
mi
from
Joplin, MO
Click here to add this to my saved trials
3535 Southern Blvd
Kettering, Ohio 45429
(937) 298-4331
Kettering Medical Center Our flagship hospital, Kettering Medical Center, stands proudly in Kettering, Ohio. From...
?
mi
from
Kettering, OH
Click here to add this to my saved trials
750 Avenue D West
Kingman, Kansas 67068
(620) 532-3147
Cancer Center of Kansas, PA - Kingman Dr. H.E. Hynes founded Cancer Center of Kansas,...
?
mi
from
Kingman, KS
Click here to add this to my saved trials
1215 E Michigan Ave
Lansing, Michigan 48912
(517) 364-1000
Sparrow Hospital Sparrow has grown to become the region's largest health system, and its diverse...
?
mi
from
Lansing, MI
Click here to add this to my saved trials
3131 La Canada St # 241
Las Vegas, Nevada 89169
(702) 693-6870
Women's Cancer Center of Nevada The Women's Cancer Center is a recognized leader in the...
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
1 Medical Center Dr
Lebanon, New Hampshire 03756
 (603) 650-5000
Dartmouth Hitchcock Medical Center Dartmouth-Hitchcock is a national leader in patient-centered health care and building...
?
mi
from
Lebanon, NH
Click here to add this to my saved trials
424 Savannah Rd
Lewes, Delaware 19958
(302) 645-3300
Beebe Medical Center Located in beautiful historic Lewes, Delaware, near Rehoboth Beach, Beebe Healthcare offers...
?
mi
from
Lewes, DE
Click here to add this to my saved trials
315 W. 15th St.
Liberal, Kansas 67905
(620) 629-6727
Cancer Center of Kansas, PA - Liberal Dr. H.E. Hynes founded Cancer Center of Kansas,...
?
mi
from
Liberal, KS
Click here to add this to my saved trials
Livonia, Michigan 48154
?
mi
from
Livonia, MI
Click here to add this to my saved trials
?
mi
from
Macon, GA
Click here to add this to my saved trials
2300 Western Ave
Manitowoc, Wisconsin 54221
(920) 320-2011
Holy Family Memorial Hospital We are the recognized leader and the largest provider of health...
?
mi
from
Manitowoc, WI
Click here to add this to my saved trials
3100 Shore Drive
Marinette, Wisconsin 54143
715.735.4200
Bay Area Medical Center Bay Area Medical Center was created in 1985, but its history...
?
mi
from
Marinette, WI
Click here to add this to my saved trials
Marshfield, Wisconsin 54449
?
mi
from
Marshfield, WI
Click here to add this to my saved trials
Mayfield Heights, Ohio 44124
?
mi
from
Mayfield Heights, OH
Click here to add this to my saved trials
9485 Mentor Ave
Mentor, Ohio 44060
(440) 205-5755
Lake University Ireland Cancer Center Lake Health is a private, not-for-profit leader in community health...
?
mi
from
Mentor, OH
Click here to add this to my saved trials
9601 Townline Rd
Minocqua, Wisconsin 54548
(715) 358-1000
Marshfield Clinic Minocqua Center The Clinic was incorporated under Wisconsin law in 1916 and operates...
?
mi
from
Minocqua, WI
Click here to add this to my saved trials
1660 Springhill Avenue
Mobile, Alabama 36604
(251) 665-8000
University of South Alabama Mitchell Cancer Institute USA Mitchell Cancer Institute (MCI) is located in...
?
mi
from
Mobile, AL
Click here to add this to my saved trials
?
mi
from
Mount Vernon, WA
Click here to add this to my saved trials
Muskegon, Michigan 49444
?
mi
from
Muskegon, MI
Click here to add this to my saved trials
100 Grand St
New Britain, Connecticut 06050
(860) 224-5011
The Hospital of Central Connecticut The Hospital of Central Connecticut is dedicated to fostering, sustaining...
?
mi
from
New Britain, CT
Click here to add this to my saved trials
4755 Ogletown-Stanton Road
Newark, Delaware 19718
302-733-1000
Christiana Care Health System - Christiana Hospital A 913-bed, 1.3-million-square-foot, modern facility in Newark, Delaware,...
?
mi
from
Newark, DE
Click here to add this to my saved trials
Newport Beach, California 92663
?
mi
from
Newport Beach, CA
Click here to add this to my saved trials
720 Medical Center Drive
Newton, Kansas 67114
(316) 282-0888
Cancer Center of Kansas, PA - Newton Dr. H.E. Hynes founded Cancer Center of Kansas,...
?
mi
from
Newton, KS
Click here to add this to my saved trials
940 NE 13th St
Oklahoma City, Oklahoma 73190
(405) 271-6458
University of Oklahoma Health Sciences Center The OU Health Sciences Center is composed of seven...
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
8303 Dodge Street
Omaha, Nebraska 68114
(402) 354–4000
Nebraska Methodist Hospital Methodist Hospital is a general medical and surgical hospital in Omaha, NE....
?
mi
from
Omaha, NE
Click here to add this to my saved trials
Orlando, Florida 32803
?
mi
from
Orlando, FL
Click here to add this to my saved trials
1902 S. US Hwy 59
Parsons, Kansas 67357
(620) 421-2855
Cancer Center of Kansas, PA - Parsons Dr. H.E. Hynes founded Cancer Center of Kansas,...
?
mi
from
Parsons, KS
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19104
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phoenix, Arizona 85012
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Pontiac, Michigan 48341
?
mi
from
Pontiac, MI
Click here to add this to my saved trials